ASX/Media RELEASE 24 April 2007Contact:Lisa Lake,...

ASX/Media RELEASE 24 April 2007
Contact:
Lisa Lake, Fleishman-Hillard
for Alimera Sciences 404-739-0152
[email protected]
Brian Leedman, Director of Investor Relations
pSivida Limited +61 8 9226 5099
[email protected]
Eva Reuter - pSivida European Public Relations
Accent Marketing Limited +49 (254) 393 0740
[email protected]
ALIMERA SCIENCES’ MEDIDUR™ TRIAL EXCEEDS 500 PATIENT MARK
IN PHASE 3 TRIAL ENROLLMENT
ATLANTA—April 23, 2007--Alimera Sciences, a privately held ophthalmic
pharmaceutical company, and global drug delivery company pSivida Limited
(NASDAQ:PSDV, ASX:PSD, Xetra:PSI) today announced that enrollment for their
Phase 3 global clinical trial, the FAME™ (Fluocinolone Acetonide in Diabetic Macular
Edema) Study has exceeded 50 percent. FAME is a double masked, randomized, multicenter
study that will follow approximately 900 patients in the U.S., Canada, Europe and
India for 36 months. The trial is studying the safety and efficacy of the novel treatment
currently referred to as Medidur for diabetic macular edema (DME).
Medidur, a tiny, injectable intravitreal insert, is being studied as a way to deliver a very
low dose of fluocinolone acetonide, a corticosteroid, to the retina for up to three years as
a treatment for diabetic macular edema (DME). Using a proprietary 25 gauge
transconjunctival injector system, an eye care professional injects the Medidur insert into
the vitreous through a minimally invasive procedure in an outpatient setting.
“Reaching this milestone in the FAME trial is a significant accomplishment for Alimera
as we continue our efforts to bring this next generation of retinal drug delivery to
market,” said Dan Myers, CEO of Alimera Sciences.
“pSivida is delighted with the progress being made in this trial and we expect successful
completion of enrollment later this year,” said Dr. Paul Ashton, Managing Director of
pSivida Limited.
Alimera Sciences and pSivida Limited announced in February 2005 a worldwide
agreement to co-develop and market the insert for the use of fluocinolone acetonide to
treat DME. The agreement also includes the option to identify, prior to February 2008,
three other compounds not previously licensed by pSivida to a third party for use in
Medidur for ophthalmic diseases. This option has the potential to result in a license to
three additional products with the Medidur insert for Alimera. Pfizer also recently
reached an agreement with pSivida to commit up to US$155 million for development
related to different ophthalmic applications of the Medidur technology.
-- more --
“As our work continues, we are pleased with recent announcements underscoring the
development interest and commitments by companies like Pfizer for this technology,”
said Myers. “It reinforces the confidence that we have in the technology as well.”
Diabetic retinopathy (DR), a complication of diabetes mellitus, is the leading cause of
blindness in the working-age population of developed countries. At any time during
progression of diabetic retinopathy, patients can develop DME which involves retinal
thickening of the macular area. There are currently more than 500,000 people with DME
in the United States and this number is expected to exceed 700,000 by the year 2010;
approximately 75,000 new cases of DME are diagnosed each year.
About Alimera Sciences Inc.
Alimera Sciences Inc., a venture backed company, specializes in the development and
commercialization of over-the-counter and prescription ophthalmology pharmaceuticals.
Founded by an executive team with extensive development and revenue growth
expertise, Alimera Sciences’ products are focused on improving the delivery of
therapeutic agents
To enhance patient’s lives and to strengthen physicians’ ability to manage ocular
conditions. For more information, please visit www.alimerasciences.com.
About pSivida Limited
pSivida is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products. Retisert® is FDA approved for the treatment of
uveitis. Vitrasert® is FDA approved for the treatment of AIDS-related CMV Retinitis.
Bausch & Lomb own the trademarks Vitrasert® and Retisert®. pSivida has licensed the
technologies underlying both of these products to Bausch & Lomb. The technology
underlying Medidur™ for diabetic macular edema is licensed to Alimera Sciences and is
in Phase III clinical trials.
pSivida owns the rights to develop and commercialize a modified form of silicon
(porosified or nano-structured silicon) known as BioSilicon™, which has applications in
drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced
BioSilicon™ product, BrachySil™ delivers a therapeutic, P32 directly to solid tumors
and is presently in Phase II clinical trials for the treatment of pancreatic cancer. For more
information, please visit www.psivida.com.
This document contains forward-looking statements that involve risks and uncertainties
including with respect to the efficacy of pSivida’s drug delivery technology and the final
results of the clinical trials described above. Although we believe that the expectations
reflected in such forward-looking statements are reasonable at this time, we can give no
assurance that such expectations will prove to be correct. Given these uncertainties,
readers are cautioned not to place undue reliance on such forward-looking statements.
Actual results could differ materially from those anticipated in these forward-looking
statements due to many important factors including those contained in cautionary
statements in the Annual Report on Form 20-F filed with the U.S. Securities and
Exchange Commission, including, without limitation, under Item 3.D, "Risk Factors"
therein. We do not undertake to update any oral or written forward-looking statements
that may be made by or on behalf of pSivida.
###